GlassScriptPhysician profile
Rolando Velazquez
NPI 1417166612
$13,021.46
in general payments reported to CMS, 2019-2025
35 companies · $2,345 in 2025
The $2,345 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,556 · 2022: $2,603 · 2023: $3,051 · 2024: $2,467 · 2025: $2,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,843 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,842.78 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,145.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,892.91 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,174.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $846.35 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $812.87 | 2021-2025 | |
| Amgen INC. | $718.34 | 2021-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $595.28 | 2021-2024 | Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $569.76 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.94 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $536.85 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $512.68 | 2021-2023 | Xarelto |
| Abbvie INC. | $419.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.04 | 2021-2023 | Trulance |
| Astellas Pharma US INC | $281.08 | 2021-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $229.67 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $188.31 | 2021-2023 | |
| Urovant Sciences INC | $129.31 | 2022 | |
| Esperion Therapeutics, INC. | $119.29 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $112.17 | 2024-2025 | Voquezna |
| Pfizer INC. | $108.94 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $97.65 | 2024-2025 | Gemtesa, Myfembree |
| Abbott Laboratories | $90.94 | 2024-2025 | Freestyle Libre |
| Averitas Pharma INC. | $84.46 | 2024-2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $67.25 | 2022-2025 | Trintellix |
| Corcept Therapeutics | $66.36 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $39.98 | 2022 | |
| Arbor Pharmaceuticals, INC. | $39.56 | 2021 | |
| Mannkind Corporation | $37.95 | 2022 | |
| Insulet Corporation | $32.28 | 2025 | Omnipod |
| Scpharmaceuticals INC. | $23.41 | 2025 | |
| Redhill Biopharma INC. | $17.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.46 | 2023 | Quviviq |
| Intuity Medical INC | $14.40 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Cequr Corporation | $12.77 | 2024 | Cequr Simplicity |
| Horizon Therapeutics Plc | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Velazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.